uniQure (NASDAQ:QURE) CFO Christian Klemt Sells 2,916 Shares of Stock

uniQure (NASDAQ:QURE) CFO Christian Klemt sold 2,916 shares of the business’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $11.32, for a total value of $33,009.12. Following the completion of the sale, the chief financial officer now directly owns 155,168 shares of the company’s stock, valued at $1,756,501.76. The trade was a 1.84 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Christian Klemt also recently made the following trade(s):

• On Tuesday, February 25th, Christian Klemt sold 14,341 shares of uniQure stock. The stock was sold at an average price of $10.70, for a total value of $153,448.70.
• On Monday, December 9th, Christian Klemt sold 1,796 shares of uniQure stock. The shares were sold at an average price of $7.55, for a total value of $13,559.80.

uniQure Stock Performance

Shares of QURE stock opened at $12.07 on Friday. The stock has a 50 day simple moving average of $15.12 and a 200-day simple moving average of $9.75. The company has a market cap of $588.33 million, a price-to-earnings ratio of -2.43 and a beta of 0.38. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a 12-month low of $3.73 and a 12-month high of $19.18.

Hedge Funds Weigh In On uniQure

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Point72 Asset Management L.P. raised its holdings in uniQure by 336.1% during the third quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock worth $4,816,000 after purchasing an additional 752,889 shares during the last quarter. Walleye Capital LLC purchased a new stake in shares of uniQure in the third quarter valued at $444,000. FMR LLC increased its stake in shares of uniQure by 8,056.6% during the 3rd quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock valued at $1,728,000 after acquiring an additional 346,274 shares during the last quarter. Sanders Morris Harris LLC increased its position in uniQure by 50.0% during the fourth quarter. Sanders Morris Harris LLC now owns 102,104 shares of the biotechnology company’s stock worth $1,803,000 after purchasing an additional 34,034 shares during the last quarter. Finally, Franklin Resources Inc. purchased a new position in shares of uniQure in the 3rd quarter worth $7,360,000. 78.83% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Raymond James upgraded shares of uniQure from an “outperform” rating to a “strong-buy” rating and upped their price target for the company from $20.00 to $52.00 in a research report on Tuesday, December 10th. Cantor Fitzgerald upped their target price on shares of uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a report on Tuesday, December 10th. Guggenheim reiterated a “buy” rating on shares of uniQure in a research note on Wednesday, December 11th. HC Wainwright boosted their price target on uniQure from $25.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, January 27th. Finally, The Goldman Sachs Group increased their price objective on uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday, December 12th. One analyst has rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $40.00.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.